Topelia is developing and commercialising its proprietary Antiviral Triple Therapy (ATT) for coronavirus infection.
Topelia’s Professor Thomas Borody has filed  patent applications with the United States Patent and Trade Mark Office (USPTO) for its ATT with all rights in the patent applications assigned to Topelia.
Professor Borody is a world leader in repurposing safe, effective drugs for new purposes. Having created the successful combination therapies Helidac (1996), Pylera (2006), and Talicia (2019), he has now combined the safe, existing drugs of zinc chelate, ivermectin, and doxycycline for the treatment of coronavirus.
The ATT offers a low-cost alternative to existing treatments currently available globally and is intended to be used on an ongoing basis in conjunction with existing vaccines to reduce the incidence and spread of coronavirus infections and its variants.
Topelia will be entitled to three years exclusivity under the United States Federal Drug Administration’s (FDA’s) “new clinical investigation exclusivity” on the ATT if certain conditions are met.
Topelia will be entitled to utilise the FDA’s Emergency Use Authorisation (EUA) pathway to obtain regulatory approval in the United States typically within a 12-month period. Topelia is led by an experienced team with a track record in pharmaceutical drug development.
Topelia is seeking AUD$35 million to undertake clinical trials on its ATT to prove its safety and efficacy, as well as obtain the necessary regulatory approvals. Through this opportunity, Topelia has the potential to achieve a liquidity event for its investors within 12 to 18 months after it obtains the EUA.